CBD and Depression: What Does the Human Research Show?
People searching for information about CBD and depression will find plenty of strong claims online. Some websites describe CBD as an antidepressant, say that it “balances serotonin” or suggest that stronger CBD oils are more effective for low mood.
The human evidence does not currently justify those claims.
There is genuine scientific interest in cannabidiol and mental health, and laboratory and animal research has explored several possible biological mechanisms. However, current human research does not establish ordinary retail CBD oil as a treatment for depression. Reviews of clinical CBD research have repeatedly highlighted how limited the evidence is for mood disorders compared with the much larger amount of preclinical research. See the systematic review on PubMed.
More recent studies have added useful information, including a 2025 randomised trial of CBD oil and a 2026 UK study involving people prescribed cannabis-based medicinal products. But neither provides evidence that a Valley CBD isolate oil treats depression.
Low mood and depression are not necessarily the same thing
Most people experience periods of low mood at some point. Depression is more persistent and can affect enjoyment of life, motivation, concentration, sleep, relationships and day-to-day functioning.
The NHS advises seeking help when symptoms of depression are present for most of the day, every day, for more than two weeks, particularly when they are affecting ordinary life. See the NHS depression guidance.
That distinction matters when looking at CBD studies because some research investigates stress, psychological distress or people considered at risk of depression, rather than patients diagnosed with major depressive disorder.
Those results should not automatically be described as evidence that CBD treats clinical depression.
Does CBD work as an antidepressant?
At present, there is not sufficient clinical evidence to say that it does.
An earlier systematic review specifically examining CBD for mood disorders concluded that the available evidence was not strong enough to recommend CBD as a treatment. At the time, researchers found no clinical trials in which CBD efficacy for a mood disorder was properly tested as the primary outcome. The review is available on PubMed.
Another systematic review of CBD in psychiatric disorders found only nine suitable clinical studies. Those concerned schizophrenia, substance-use disorders and social anxiety — not major depression — and overall psychiatric results were considered inconclusive.
Research has developed since those reviews, however, so newer studies deserve careful examination.
What did the 2025 CBD and depression-risk study find?
A particularly useful randomised controlled trial was published in November 2025.
Researchers recruited 180 highly stressed university students considered at risk of depression. Participants were randomly allocated to use a low-dose 10% full-spectrum CBD oil, a placebo oil or no treatment for 30 days. The study can be read on PubMed.
After the intervention, both the CBD group and the placebo group showed greater reductions in stress, depressive symptoms and some measures of psychological distress compared with the no-treatment group.
At first glance, that might sound like evidence that CBD helped.
But there was an extremely important finding:
There was no significant difference between CBD and placebo on any of the outcomes studied.
In other words, people taking the CBD oil improved, but people taking an inactive placebo oil improved by a similar amount.
That means the study did not demonstrate a specific antidepressant effect from CBD.
There are other important limitations. The participants were stressed university students considered at risk of depression, rather than a clinical trial population being treated for diagnosed major depressive disorder. The intervention lasted only 30 days, and the product was a full-spectrum CBD oil rather than purified CBD isolate.
This is exactly why simply reporting that “people taking CBD improved” can be misleading unless we also look at what happened to the placebo group.
What about the 2026 UK medical cannabis study?
Another important study was published in 2026 using data from the UK Medical Cannabis Registry.
Researchers analysed 698 patients whose primary indication was depression and who had been prescribed cannabis-based medicinal products. They followed patient-reported outcomes for up to 24 months. The study is available on PubMed.
Scores measuring depression, anxiety, sleep and health-related quality of life improved compared with baseline, with some of the largest changes appearing during the first few months.
This is interesting clinical evidence and should not be dismissed.
But it does not prove that CBD treated the depression.
The researchers themselves emphasised that the study design could not establish causation. There was no randomised placebo group with which to compare the patients, and the study examined prescribed cannabis-based medicinal products, not ordinary retail CBD isolate.
Cannabis-based medicinal products can contain different combinations and concentrations of cannabinoids, including CBD and THC.
The appropriate conclusion is therefore:
Patients prescribed cannabis-based medicines reported improvements, but this observational study cannot tell us whether the products caused those improvements or whether CBD itself was responsible.
The researchers concluded that the findings support further controlled research to establish efficacy.
What about serotonin and CBD?
CBD has been investigated for interactions involving several signalling systems, including serotonin receptors, particularly the 5-HT1A receptor.
This is scientifically interesting, and preclinical research has produced antidepressant-like findings in experimental models. Reviews also discuss possible effects involving serotonin signalling, the endocannabinoid system, neuroplasticity and other biological pathways. See this review on PubMed.
But understanding a possible mechanism is not the same thing as demonstrating that a product treats depression.
A molecule interacting with a receptor does not automatically mean that taking a retail product will improve a diagnosed mental health condition.
That is why we should not claim that CBD's interaction with 5-HT1A receptors produces antidepressant effects or helps people maintain a stable and positive mood.
What about CBD and neurogenesis?
Animal and laboratory studies have also investigated whether CBD may influence processes involved in neuroplasticity and neurogenesis.
Again, this is an area of scientific research rather than evidence that CBD oil has been clinically proven to improve depression in people. The gap between preclinical mechanisms and proven clinical treatments can be substantial.
For a retail CBD website, the responsible approach is to explain that research exists without converting experimental biological findings into consumer health promises.
CBD, THC and medical cannabis are not interchangeable
This distinction is important throughout CBD research.
CBD isolate, full-spectrum CBD oil, cannabis and prescribed cannabis-based medicines are not the same thing.
A clinical study involving a THC-containing medical cannabis product cannot automatically be used as evidence about purified CBD.
Likewise, the 2025 trial used a full-spectrum CBD oil, whereas Valley CBD's current oils are made with CBD isolate.
That means we should neither claim that those studies prove Valley CBD works for depression nor dismiss relevant cannabinoid research entirely.
We should identify what researchers actually tested.
Does stronger CBD mean a stronger antidepressant effect?
No evidence currently establishes that a higher-strength retail CBD oil produces a greater antidepressant effect.
Product strength tells you how much CBD is contained in a particular volume. It does not tell you whether that product treats depression.
That distinction is particularly important for a company selling high-strength CBD.
Using language such as “high-strength CBD for depression” can unintentionally imply that higher concentration provides greater medical effectiveness. Current evidence does not support that conclusion.
Higher concentration can also make it easier to consume more CBD in a smaller amount, which makes total exposure an important separate safety consideration.
What does the FSA currently say about CBD?
Current Food Standards Agency guidance advises healthy adults consuming CBD foods to limit total CBD intake to 10mg per day. See the FSA guidance on CBD safety and health claims.
The FSA also says there are no authorised health claims for CBD food products and that CBD foods should not be marketed with claims that they treat illness or provide medical benefits.
People taking medication are among the groups the FSA advises to avoid CBD unless under medical direction because of potential interactions and gaps in safety evidence. The same caution applies to people who are pregnant, breastfeeding or trying to conceive, and to people under 18.
That medication warning is particularly important in an article about depression because someone reading it may already be taking an antidepressant or another prescription medicine.
Can CBD be taken with antidepressants?
This is not something a CBD retailer should advise on for an individual customer.
CBD can interact with medicines, and current FSA advice is that people taking medication should avoid CBD unless under medical direction.
Someone taking an antidepressant should therefore discuss CBD with an appropriate healthcare professional rather than stopping medication, changing medication or adding CBD based on information from a commercial website.
Can CBD replace antidepressants or therapy?
There is no evidence basis for recommending retail CBD as a replacement for an established depression treatment.
NICE's current guideline for depression in adults was reviewed again in January 2026, and the recommendations were retained. Depending on the severity of depression and the individual's circumstances and preferences, recommended approaches include psychological treatments such as cognitive behavioural therapy and behavioural activation, antidepressant medicines, and combinations of psychological treatment and medication. CBD is not listed as a recommended treatment for depression. See the NICE recommendations.
For less severe depression, NICE says antidepressants should not routinely be offered first-line unless that is the person's informed preference. For more severe depression, treatment options include individual CBT, antidepressant medication and combinations of treatment, with decisions made according to individual needs and preferences.
The important point is not that everyone with depression needs medication.
It is that CBD has not earned the evidence base required to replace established clinical options.
Why medical claims matter for CBD retailers
This is not only a scientific issue.
The MHRA states that CBD products used for medical purposes are medicines. A company marketing a CBD-containing product with a medicinal claim can bring that product within the definition of a medicinal product under UK medicines legislation. See the MHRA statement on CBD products.
For Valley CBD, an article can legitimately discuss studies into CBD and depression.
What we should not do is move from:
“Researchers are investigating CBD and depression.”
to:
“Our CBD supports depression, serotonin, mood or emotional balance.”
Those are very different statements.
When should somebody seek help for depression?
A period of low mood does not necessarily mean someone has clinical depression.
However, the NHS recommends seeking professional help when symptoms persist for more than two weeks or begin to interfere significantly with ordinary life, relationships or work. See the NHS guidance on low mood and depression.
Thoughts of suicide or self-harm need particular attention. Someone who feels they may be in immediate danger should seek urgent NHS or emergency help rather than attempting to manage the situation themselves with CBD or another supplement.
Frequently asked questions
Can CBD help depression?
Current human evidence does not establish retail CBD as an effective treatment for depression. A recent randomised study found improvement among people taking CBD, but the CBD group did not perform significantly better than the placebo group.
Does CBD increase serotonin?
Researchers have investigated CBD's interaction with serotonin signalling, including 5-HT1A receptors, but a possible biological mechanism does not demonstrate that CBD treats depression in humans.
Has CBD been clinically tested for depression?
Research is developing, but the clinical evidence remains limited. The 2025 randomised CBD-oil study involved stressed students at risk of depression rather than patients being treated for major depressive disorder, and CBD was not superior to placebo.
What does the UK medical cannabis research show?
A 2026 observational study of 698 UK patients prescribed cannabis-based medicinal products found improvements in patient-reported depression and several other outcomes. However, because it was an uncontrolled observational study, the researchers said that causation could not be established.
Is CBD isolate the same as medical cannabis?
No. CBD isolate is predominantly cannabidiol, whereas cannabis-based medicinal products can contain different cannabinoids and formulations. Evidence involving medical cannabis should not automatically be attributed to CBD isolate.
Is high-strength CBD better for depression?
There is currently no good evidence establishing that a higher CBD concentration produces a greater antidepressant effect.
Can CBD replace antidepressants?
CBD is not established as a replacement for antidepressants or psychological therapy. People receiving treatment for depression should not stop or alter that treatment because of claims about CBD on a retail website. Current NICE treatment guidance does not recommend CBD for depression.
Can I use CBD while taking antidepressants?
The FSA advises people taking medication to avoid CBD unless under medical direction because CBD can interact with medicines.
The bottom line
CBD is an interesting area of mental-health research, but current human evidence does not establish ordinary CBD oil as a treatment for depression.
The strongest recent randomised CBD study found that CBD was not significantly better than placebo. Meanwhile, observational UK medical-cannabis research has reported encouraging improvements among prescribed patients, but those studies cannot demonstrate that CBD itself caused the changes.
Laboratory findings involving serotonin receptors, neuroplasticity or the endocannabinoid system are worthwhile areas of research, but they should not be converted into claims that a retail CBD product improves mood or treats depression.
We can explain what researchers have investigated, what they found and where the evidence remains uncertain. We should not claim that Valley CBD oils treat depression, increase happiness, balance serotonin or provide emotional or mental-health benefits.
That approach is more scientifically accurate and consistent with current FSA and MHRA guidance.
This article provides general information about published research and current UK guidance. It is not medical advice and does not recommend CBD as a treatment for depression.